Expected High Growth Market Segments in Molecular Diagnostic Testing

  • ID: 4451242
  • Report
  • Region: Global
  • 45 Pages
  • Kalorama Information
1 of 3

Molecular testing provides fast and accurate results and the prescence of molecular tests has disrupted several testing markets over the past decade and a half. However, some segments have thrived and others are seeing mature growth levels. This report details the highest revenue growth areas of molecular testing, as considered by manufacturers of IVD instruments, reagents and supplies. The report covers both high-growth product segments and regional markets of significance.

Expected High Growth Market Segments in Molecular Diagnostic Testing Provides:

  • High-Growth Areas in Molecular Infectious Disease Testing
  • High-Growth Areas in Molecular Cancer Testing
  • High-Growth Areas in Other Molecular Testing
  • High-Growth Regions
  • Overview of Molecular Test Technologies.
  • Top Companies in High-Growth Molecular Testing Markets
  • Conclusions and Projections to 2021

Clinical molecular diagnostics refer to in vitro diagnostic (IVD) tests used in patient health care that detect, quantify or characterize nucleic acid analytes, whether pathogenic nucleic acid, patient DNA or patient RNA. As an IVD market, molecular diagnostics refer to the relevant test kits, other reagents and instruments that are used for clinical testing in settings that include reference laboratories, independent labs, hospital labs, other centralized clinical labs and near-patient testing sites such as clinics and physician offices.

The Major Applications of Clinical Molecular Diagnostics

Coverage in this report includes: Infectious disease diagnostics such as molecular microbiology and virology, including the detection, identification, quantification and nucleic-acid based resistance or susceptibility profiling of pathogens; Blood Transfusion Diagnostics, nucleic acid screening (NAT) of donated blood, often pooled samples, for the detection of active infections responsible for transfusion transmitted infections (TTIs); ancillary market for molecular immunohematology or blood typing; Histology / cytology diagnostics , which is largely synonymous with in situ hybridization (ISH) methods that use direct hybridization of chromogenic (CISH) or fluorescent (FISH) nucleic acid probes within slided tissue or suspended cell samples viewed under microscopy;Molecular Cancer Diagnostics, which are tissue, blood and urine samples can be assayed using nucleic acid amplification tests (NAATs) or sequencing to diagnose, prognose and identify key mutations for targeted therapies; future; Transplant diagnostics - various PCR-based methodologies, Sanger sequencing and NGS used to type HLA alleles in low to high resolution in order to match donors and recipients for solid organ and hematopoietic stem cell (HSCT) or bone marrow transplants, as well as post-transplant monitoring. The report also covers Inherited disease diagnostics - diagnosis of rare genetic diseases andother inherited traits including pharmacodiagnostic (pharmacokinetic) traits;major area of application is thrombophilia markers and anticoagulant response markers

Infectious disease is projected to account for 60% of the global molecular diagnostics market by 2021.The market segment is defined by test decentralization with the introduction of NAAT platforms able to be operated in hospital labs and near-patient points of care such as physician office labs (POLs) and outpatient clinics. Integrated design from sample preparation to results analysis and user friendly features are just as appealing to larger clinical labs to free up personnel. Menu expansion on integrated analyzers has been the predominant focus of competitors in molecular infectious disease diagnostics. Market share and client retention depend on the ability of one platform to perform all routine infectious disease tests.

The development of molecular tests has been prioritized for all recent disease threats, notably Ebola and Zika virus. While immunoassays are preferred for routine screening and by cost-constrained labs, molecular tests offer optimal sensitivity and specificity key to public health response,diagnosis, and targeted treatment. Infectious diseases range from the common flu to antimicrobial resistant inpatient infections and engage all levels of healthcare and thus represent the largest market for molecular diagnostics.

Note: Product cover images may vary from those shown
2 of 3

1: Executive Summary

Molecular Diagnostic Technologies
Molecular Diagnostics in Healthcare

Figure 1-1: High Growth Molecular Testing Markets Compared to IVD Average and Molecular Average

Figure 1-1: Growth of Regional Molecular Diagnositcs Markets Compared

2: Analysis: High-Growth Markets For Molecular Diagnostics

Table 2-1
High Growth Categories in the Infectious Disease Molecular Diagnostics Market Market Size in 2016 and Forecast to 2021
Table 2-2
High-Growth Regions for Infectious Disease Diagnostics Market (2016-2021)
High Growth Infectious Disease Market Area #1
High Growth Infectious Disease Market Area #2
High Growth Infectious Disease Market Area #3
High Growth Infectious Disease Market Area #4
High Growth Infectious Disease Market Area #5
High Growth Infectious Disease Market Area #6
Table 2-3
High Growth Regions, NAT Blood Screening Market Market Size 2016 and Forecast to 2021
High Growth Cancer Market Area #1
Table 2-4
High Growth Cancer Testing Areas, Market Size 2016 and Forecast 2021
Table 2-5
Molecular Cancer Testing High Growth Regions
High Growth Cancer Market Area #2
High Growth Cancer Testing Regional Markets
High Growth Other Market Area #1
Table 2-8
Other Molecular Testing High-Growth Areas, Market Size 2016 and Forecast 2021
High Growth Regional Markets for Other Testing
Table 2-8
High-Growth Regional Markets for Other Molecular Diagnostics Testing
High Growth Other Moleuclar Testing Market Area #2

Note: Product cover images may vary from those shown
3 of 3


4 of 3
Note: Product cover images may vary from those shown